DESMOID TUMORS MARKET ANALYSIS

Desmoid tumor are connective tissue growths that are not malignant. Desmoid tumors typically develop in the arms, legs, and belly. Desmoid tumor are also referred to as aggressive fibromatosis. Some desmoid tumor grow slowly and don't need to be treated right away. Others have a rapid rate of growth and are treated with surgery, chemotherapy, radiation therapy, or other medications.

Global desmoid tumors market is estimated to be valued at US$ 2,494.1 million in 2022 and is expected to exhibit a CAGR of 7.3% during the forecast period (2022-2030).

Figure 1.Global Desmoid Tumors Market Share (%), by Drug Type, 2022

To learn more about this report, request sample copy

Global Desmoid Tumors Market - Drivers

Robust pipeline of novel drugs for treatment of desmoid tumors is expected to drive market growth over the forecast period. For instance, in June 2022, Iterion Therapeutics, a venture-backed clinical-stage biotechnology company exploring innovative cancer therapeutics, announced that findings from a Phase 1 study of tegavivint in patients with desmoid tumors would be highlighted in a poster presentation and discussion session at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO 2022), a meeting for conducting scientific events for oncology professionals, patient advocates, industry representatives, and major media outlets worldwide.

Increase in the technological advancements in desmoid tumor treatment is expected to drive market growth over the forecast period. For instance, in June 2021, Profound Medical, a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced that its Sonalleve Magnetic Resonance-guided High Intensity Focused Ultrasound (MR-HIFU) system had received the Conformité Européenne (CE) mark for the treatment of desmoid tumors. Traditional treatment options include radiofrequency ablation and surgery, which carry unique risks for patients. Sonalleve combines real-time MR imaging and thermometry with thermal ultrasound to enable precise, noninvasive ablation of diseased tissue. The treatment offers desmoid tumor patients with a treatment that can be performed safely with clinical improvement without the risks of invasive procedures, surgery, ionizing radiation exposure, or anesthesia. MR-HIFU offers a valuable treatment option for the often difficult to treat desmoid tumors. The potential benefits of MR-HIFU treatment is thought to outweigh the risks for patients, as MR-HIFU treatment can be repeated in case of recurrent disease with limited side-effects in contrary to the conventional treatment methods.

Figure 2.Global Desmoid Tumors Market Share (%), by Region, 2022

To learn more about this report, request sample copy

Global Desmoid Tumors Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

Disruptions in routine and emergency medical care access and delivery have been observed during the COVID-19 pandemic. According to data published on the Centers for Disease Control and Prevention, in September 2020, an estimated 40.9% of the U.S. adults have avoided medical care during the pandemic because of concerns about COVID-19, including 12% who avoided urgent or emergency care and 31.5% who avoided routine care.  Many surgeries and different types of therapies have been postponed due to COVID-19. The desmoid tumor market had negative impact during the COVID-19 pandemic as the number of therapies were postponed or cancelled. According to data published on Elsevier in January 2021, in 2020, radiation therapy courses fell by 19·9% in April, 6·2% in May, and 11·6% in June compared with corresponding months in 2019 in the U.K. Moreover, COVID-19 has placed a tremendous strain on sustaining the clinical trails. According to the ClinicalTrials.gov report 2020, the challenges faced in conducting clinical research during the pandemic led to the termination of more than 2,000 registered clinical trails

Global Desmoid Tumors Market: Key Developments

In May 2022, SpringWorks Therapeutics, a clinical-stage biopharmaceutical company, announced positive topline findings from the double-blind placebo controlled phase 3 DeFi trial (NCT03785964), assessing the use of nirogacestat as a treatment for adult patients with progressing desmoid tumors.

In September 2022, Ayala Pharmaceuticals announced that the U.S. Food and Drug Administration had granted a fast track designation to AL102 for the treatment of patients with progressing desmoid tumors.

Global Desmoid Tumors Market: Restraint

The major factors that hinder growth of the global desmoid tumors market include high cost of desmoid tumors treatment drugs and side effects associated with chemotherapy and other desmoid tumor drugs. Many people who have had cancer treatment such as chemotherapy and radiation therapy have a risk of developing long-term side effects. These side effects can happen months or years after treatment, which is expected to act as a restraint for the market growth.For instance, chemotherapy and radiation therapy can cause some serious heart problems, lung problems, endocrine system problems, hormonal problems such as infertility, brain, spinal cord, and nerve problems, oral health and vision problems, digestion problems, among others.

Global Desmoid Tumors Market - Key Players

Major players operating in the global desmoid tumors market include Horizon Therapeutics Plc, Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals PLC,  Natco Pharma Ltd,  Lupin,  Zydus Lifesciences, Mylan N.V.,  Assertio Holdings, Inc.,  Mayne Pharma Group Limited, Alembic Pharmaceuticals Limited,  Aprazer, Ayala Pharmaceuticals,  SpringWorks Therapeutics, Inc.,  Iterion Therapeutics, Novartis AG, Apotex Inc.,  Bayer AG., Sun Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd., Endo International plc, Abbott, and Getwell Pharmaceuticals